ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) finished Friday with a subtraction of -$0.03 to close at $15.92, a downside of -0.19 percent. An average of 953,720 shares of common stock have been traded in the last five days. There was a gain of $0.10 in the past week, and it reached a new high 10 times over the past 12 months. The last 20 days have seen an average of 1,067,955 shares traded, while the 50-day average volume stands at 1,204,708.
ACAD stock has increased by 2.18% in the last month. The company shares reached their 1-month lowest point of $14.45 on 12/08/22. With the stock rallying to its 52-week high on 04/07/22, shares of the company touched a low of $12.24 and a high of $28.06 in 52 weeks. It has reached a new high 9 times so far this year and lost -31.79% or -$7.42 in price. In spite of this, the price is down -43.25% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
ACAD stock investors should be aware that ACADIA Pharmaceuticals Inc. (ACAD) stock had its last reported insider trading activity 40 days ago on Nov 21. In this transaction, the insider spent $27,834. President, Stankovic Srdjan R., disposed of 1,326 shares at a price of $15.81 on Oct 15. The insider now owns more than $20,964 worth of shares. Prior to that, CEO DAVIS STEPHEN went on to Sale 2,804 shares at $15.81 each on Oct 15. An amount of $44,331 was transacted.
ACADIA Pharmaceuticals Inc. (ACAD) stock’s beta is 0.58. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 5.15, the price-to-book (PB) ratio at 6.05.
The quick ratio of ACADIA Pharmaceuticals Inc. for the three months ended June 29 was 4.40, and the current ratio was 4.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $473.3 million compared to revenue of $484.14 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, ACADIA Pharmaceuticals Inc.’s return on assets was -34.20%.
For the three-month period that ended June 29, ACADIA Pharmaceuticals Inc. had $281.74 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$27.18 million in the quarter, while revenues were grew 46.8%. The analyst consensus anticipated ACADIA Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.25 per share, but it turned out to be -$0.21, a 16.00% surprise. For the quarter, EBITDA amounted to -$31.55 million. Shareholders own equity worth $161.93 million.
From a technical analysis perspective, let’s take a brief look at ACADIA Pharmaceuticals Inc. (ACAD) price momentum. RSI 9-day as of the close on 30 December was 59.47%, suggesting the stock is Neutral, with historical volatility in this time frame at 34.91%.
As of today, ACAD’s price is $15.58 +0.63% or $0.10 from its 5-day moving average. ACAD is currently trading +3.78% higher than its 20-day SMA and -1.85% lower than its 100-day SMA. However, the stock’s current price level is +2.05% above the SMA50 and -30.93% below the SMA200.
The stochastic %K and %D were 72.89% and 62.77%, respectively, and the average true range (ATR) was 0.62. With the 14-day stochastic at 83.77% and the average true range at 0.63, the RSI (14) stands at 55.89%. The stock has reached 0.21 on the 9-day MACD Oscillator while the 14-day reading was at 0.20.
Goldman downgraded ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) to a a Sell rating in its most recent analyst report. Previously, the stock was rated as a Neutral.
What is ACAD’s price target for the next 12 months?
Analysts predict a range of price targets between $10.00 and $25.00, with a median target of $17.50. Taking a look at these predictions, the average price target given by analysts for ACADIA Pharmaceuticals Inc. (ACAD) stock is $18.39.